Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Immunome, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON MAY 1, 2026, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 450,000 SHARES OF COMMON STOCK TO NINETEEN NEW EMPLOYEES UNDER THE COMPANY'S 2024 INDU.

IMMUNOME REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY COMMITTED TO DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED THE SUBMISSION OF A NEW DRUG APPLICATION (NDA) TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR VAREGACESTAT, AN INVESTIGATIONAL, ORAL, ONCE-DAILY GAMMA SECRETASE INHIBITOR (GSI), FOR THE TREATMENT OF ADULTS WITH DESMOID TUMORS. THE VAREGACESTAT NDA SUBMISSION MARKS AN IMPORTANT MILESTONE FOR IMMUNOME. IT R.

IMMUNOME ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO U.S. FDA FOR VAREGACESTAT FOR THE TREATMENT OF ADULTS WITH DESMOID TUMORS

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (IMMUNOME) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY DEDICATED TO DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED THAT DATA FROM RINGSIDE, ITS GLOBAL, PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF VAREGACESTAT IN PATIENTS WITH PROGRESSING DESMOID TUMORS, HAS BEEN SELECTED FOR PRESENTATION IN AN ORAL ABSTRACT SESSION AT THE 2026 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING, TAKING PLACE MAY 2.

IMMUNOME ANNOUNCES ORAL PRESENTATION OF PHASE 3 RINGSIDE DATA AT 2026 ASCO ANNUAL MEETING

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON APRIL 1, 2026, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 188,500 SHARES OF COMMON STOCK TO THIRTEEN NEW EMPLOYEES UNDER THE COMPANY'S 2024 IN.

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON MARCH 2, 2026, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 282,000 SHARES OF COMMON STOCK TO SEVEN NEW EMPLOYEES UNDER THE COMPANY'S 2024 INDUC.

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FULL YEAR ENDED DECEMBER 31, 2025, AND PROVIDED A BUSINESS UPDATE. IMMUNOME MADE SUBSTANTIAL PROGRESS IN 2025. THE POSITIVE PHASE 3 RINGSIDE RESULTS REPRESENT A SIGNIFICANT MILESTONE FOR PATIENTS LIVING WITH DESMOID TUMORS AND WILL SUPPORT OUR PLANNED NDA SUBMISSION FOR VAREGACESTAT IN.

IMMUNOME REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED THAT MEMBERS OF IMMUNOME'S MANAGEMENT WILL PRESENT AT THE FOLLOWING INVESTOR CONFERENCES: TD COWEN 46TH ANNUAL HEALTH CARE CONFERENCE PRESENTATION DATE/TIME: MARCH 3, 2026, AT 9:50 A.M. ET LEERINK PARTNERS GLOBAL HEALTHCARE CONFERENCE PRESENTATION DATE/TIME: MARCH 10, 2026, AT 3 P.M. ET INTERESTED PARTIES CAN AC.

IMMUNOME TO PRESENT AT UPCOMING INVESTOR CONFERENCES

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON FEBRUARY 2, 2026, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 30,000 SHARES OF COMMON STOCK TO ONE NEW EMPLOYEE UNDER THE COMPANY'S 2024 INDUCE.

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON JANUARY 2, 2026, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 93,000 SHARES OF COMMON STOCK TO THREE NEW EMPLOYEES UNDER THE COMPANY'S 2024 INDU.

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED THAT IMMUNOME MANAGEMENT WILL PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE ON WEDNESDAY, JANUARY 14, 2026 AT 10:30 A.M. PST. INTERESTED PARTIES CAN ACCESS A LIVE AUDIO WEBCAST OF THE PRESENTATION VIA THE INVESTOR RELATIONS SECTION OF IMMUNOME'S WEBSITE AT WWW.IMMUNOME.COM. A REPLAY WEBCAST WILL B.

Immunome, Inc.

IMNM

Price

Financial Reports

No items found.

Press Releases

Immunome, Inc.

IMNM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

IMNM